Fani PANTOULI | Postdoctoral Fellow | BSc MSc PhD | Cleveland Clinic, OH | Florida Research and Innovation | Research profile
PDF) 6-bromo-indirubin-3′-oxime (6BIO), a Glycogen synthase kinase-3β inhibitor, activates cytoprotective cellular modules and suppresses cellular senescence-mediated biomolecular damage in human fibroblasts
Dr. Lauren Giugale, MD – Pittsburgh, PA | Obstetrics & Gynecology
Colorado Volleyball
Elixrison Villas | Lefkáda
Small Molecule Activators of the Heat Shock Response: Chemical Properties, Molecular Targets, and Therapeutic Promise | Chemical Research in Toxicology
Vaccines | Free Full-Text | Factors Influencing Level and Persistence of Anti SARS-CoV-2 IgG after BNT162b2 Vaccine: Evidence from a Large Cohort of Healthcare Workers
Immunogenicity of anti-SARS-CoV-2 Comirnaty vaccine in patients with lymphomas and myeloma who underwent autologous stem cell transplantation | Bone Marrow Transplantation
Elixrison Villas | Lefkáda
5663 PDFs | Review articles in CRE RECOMBINASE
Elena Studios Athani Lefkada | Lefkáda
Harris PRATSINIS | Senior Researcher | PhD | National Center for Scientific Research Demokritos, Athens | ncsr | Institute of Biosciences and Applications (IB-A) | Research profile
Elixrison Villas | Lefkáda
Elixrison Villas | Lefkáda
Olive-Oil-Derived Oleocanthal Enhances β-Amyloid Clearance as a Potential Neuroprotective Mechanism against Alzheimer's Disease: In Vitro and in Vivo Studies | ACS Chemical Neuroscience
Fani PANTOULI | Postdoctoral Fellow | BSc MSc PhD | Cleveland Clinic, OH | Florida Research and Innovation | Research profile
Οδός Γέλιου - Οδός Γέλιου added a new photo.
Frontiers | Immune Responses Against SARS-CoV-2 WT and Delta Variant in Elderly BNT162b2 Vaccinees
Elena Studios Athani Lefkada | Lefkáda
ALPP - Lactation Counselors and Consultants Near You
PDF) Neutralizing antibodies to Omicron after the fourth SARS-CoV-2 mRNA vaccine dose in immunocompromised patients highlight the need of additional boosters
Frontiers | Neutralizing antibodies to Omicron after the fourth SARS-CoV-2 mRNA vaccine dose in immunocompromised patients highlight the need of additional boosters